
Saturday, April 22, 2017 5:05:29 PM
Did both parents fast 12 hrs before the lipid panels
Did both have blood draws or were these finger prick samples
Are either of them on existing meds ...Statins , BP meds etc
How far apart are the samples ...3 mths or a yr .
Any pre existing conditions , and family history of CAD.
I'd be particularly interested if there was any change in diet , exercise etc between the samples ...even small changes like walking more , eating chicken / fish instead of steak .
If they aren't on other meds and you have persuaded them to take Vascepa ...indicates they are interested in lowering their risk . Just wondering if that change extends to other aspects of their diet and life style.
Relates to my theory re R-IT ...ie The act of signing up for a RCT and taking a "known " healthy product indicates an interest in reducing ones risk and that this behavior extends to other aspects of diet and life style choices for both arms of R-IT.
Also think that Amarin wanted a second Interim to reduce drop outs
JMO
Kiwi
Recent AMRN News
- Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering • GlobeNewswire Inc. • 02/27/2025 02:00:00 PM
- Amarin Receives National Reimbursement for VAZKEPA® in Austria • GlobeNewswire Inc. • 02/25/2025 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025 • GlobeNewswire Inc. • 02/19/2025 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2025 09:45:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2025 09:45:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/31/2025 09:45:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2025 10:00:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2025 10:00:06 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2025 10:00:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/18/2024 09:15:07 PM
- Amarin Receives National Reimbursement for VAZKEPA® in Italy • GlobeNewswire Inc. • 12/16/2024 12:00:00 PM
- Amarin Appoints Peter Fishman Chief Financial Officer • GlobeNewswire Inc. • 12/13/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/22/2024 09:49:38 PM
- Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual • GlobeNewswire Inc. • 11/11/2024 01:00:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/31/2024 08:42:24 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 10/30/2024 08:10:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2024 08:10:08 PM
- Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 10/30/2024 08:05:00 PM
- Amarin Announces Two Upcoming Investor Events • GlobeNewswire Inc. • 10/01/2024 12:00:00 PM
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
FEATURED ConnectM Eliminates an Additional $1.9 Million of Debt • Feb 27, 2025 4:01 PM
Consumer Automotive Finance, Inc. Announces Nationwide Teleconference as It Transitions to Fifty 1 Labs, Inc. • CAFI • Feb 27, 2025 9:00 AM
VPR Brands Secures Settlement Agreement With POP Vapor, Reinforcing Commitment to Intellectual Property Protection • VPRB • Feb 27, 2025 8:49 AM
Wytec Begins Sales of Its Multi-Government AI Threat Detection Sensor Technology • WYTC • Feb 27, 2025 7:05 AM
VAYK Issues Clerical Correction to Feb 18 News Regarding Shareholder Premium • VAYK • Feb 26, 2025 10:32 AM
UAV Corp. Unveils Strategic Milestones in X Spaces Teleconference • UMAV • Feb 26, 2025 8:30 AM